As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
Aims and scope
EJNMMI Radiopharmacy and Chemistry publishes new research in the field of development of new imaging and radionuclide-based therapeutic agents for application in nuclear medicine and molecular imaging. The journal provides a platform for chemists, pharmacists and basic scientists to present their views and scientific work. In addition, the journal provides insight into novel concepts of imaging or radionuclide-based therapeutic agent applications of relevance for the whole molecular imaging community.
The journal reports original research articles, review papers, guidelines on the application of imaging or radionuclide therapy agents, editorials, and letters to the editor. Research articles on novel radiochemistry, new radiopharmaceuticals including their first biological evaluation, molecular imaging agents including optical imaging, MRI, and hybrid probes, are the main focus of the journal. To translate imaging and radionuclide therapy agents to the clinic, legislative issues related to their production and safety can be presented as well in the form of guidelines or position papers.
COVID-19 and impact on peer review
Articles
-
-
Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals
-
Immune cell labelling and tracking: implications for adoptive cell transfer therapies
-
Production, purification, and radiolabeling of the 203Pb/212Pb theranostic pair
-
Highlight selection of radiochemistry and radiopharmacy developments by editorial board (January–June 2020)
-
Guidance on validation and qualification of processes and operations involving radiopharmaceuticals
-
18th European Symposium on Radiopharmacy and Radiopharmaceuticals
-
Targeting of activated fibroblasts for imaging and therapy
-
New protein deposition tracers in the pipeline
The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13
-
Production of novel diagnostic radionuclides in small medical cyclotrons
EJNMMI Journal Family
Discover featured content, editor’s highlights, and the latest research via our Gateway to the EJNMMI Journal Family.
Annual Journal Metrics
-
Speed
46 days to first decision for reviewed manuscripts
43,3 days to first decision for all manuscripts
94,3 days from submission to acceptance
35 days from acceptance to publicationUsage
53,789 Downloads
29 Altmetrics Mentions
Need help with APC funding?
We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here.
Check if your institution is a member
More than 500 institutions have partnered with BMC through the membership program. As an affiliated Author from a member institution, you may be entitled to submit your manuscript without paying the article processing charge (APC) or with a discount. Check here if your institution is a member!
EJNMMI Radiopharmacy and Chemistry is a new journal within the EJNMMI family to publish research in the field of new imaging and radionuclide-based therapeutic agents that can be applied in nuclear medicine and molecular imaging. There is a great need for better and more specific imaging agents for better diagnosis and understanding of disease. This will finally enable improvement of patient treatment. The combination of different molecular imaging modalities to obtain the optimal diagnostic information will be bolstered by the development of hybrid imaging probes. The number of applications of radionuclide therapy is increasing and more effective radiotherapeutic agents are urgently needed. Thus it can be concluded that radiopharmacy and radiochemistry are very essential for the development of nuclear medicine and molecular imaging and for its position in personalized medicine.
This new journal provides an ideal platform for chemists, pharmacists and basic scientists to promote science, but also to exchange opinions and to provide updates on developments that have an effect on the availability of imaging agents for the clinic, such as regulatory aspects. By accepting original research articles, review papers, guidelines on the application of imaging or radionuclide therapy agents, editorials, and letters to the editor I hope to establish a unique platform for our community.
- ISSN: 2365-421X (electronic)
